Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2024-08-22 Annual Report
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
2024 Full Year Results Media Release 7 pages 412.1KB
Annual Report Classification · 95% confidence The document is a detailed announcement dated 23 August 2024 from Mayne Pharma Group Limited reporting its financial results for the fiscal year ended 30 June 2024 (FY24). It includes comprehensive financial data such as revenue, gross profit, EBITDA, segment performance, cash flow, and outlook. The document also references an investor webcast and presentation slides related to the FY24 results. The length of the document (approximately 15,000 characters) and the inclusion of substantive financial data and analysis indicate this is a full financial report rather than a brief announcement or a presentation alone. The content aligns with the characteristics of an Annual Report or a full Yearly Financial Report. However, since it is specifically titled as a financial results announcement and includes detailed financial performance for the full fiscal year, it fits best under the category of an Annual Report (10-K equivalent) for the fiscal year 2024. Therefore, the appropriate classification is Annual Report (10-K). FY 2024
2024-08-22 English
2024 Full Year Results Investor Presentation 35 pages 1.4MB
Investor Presentation Classification · 95% confidence The document is titled 'FY24 Results Presentation' and contains detailed financial performance data for the fiscal year 2024, including revenue, EBITDA, cash flow, segment performance, and operational highlights. It includes forward-looking statements, non-IFRS financial measures, and detailed commentary on financial results and business segments. The length is about 15,000 characters, indicating a comprehensive presentation rather than a brief announcement. The content is consistent with an investor presentation focusing on financials, strategy, and market position rather than a formal annual report or earnings release. There is no indication that this is a transcript, audit report, or regulatory filing. Therefore, the document best fits the category of an Investor Presentation (IP).
2024-08-22 English
Notification of date for release of FY24 results 1
Report Publication Announcement Classification · 95% confidence The document is an ASX announcement dated 15 August 2024, stating that Mayne Pharma Group Limited will release its full year financial results for the year ended 30 June 2024 on 23 August 2024. It also announces a webcast of the results on the same day. The document does not contain the actual financial statements or detailed financial data, but rather informs about the upcoming release and the investor call. The document length is short (1602 characters) and serves as a notice or announcement rather than the report itself. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) because it announces the timing and availability of the full annual results report and webcast, but does not include the report itself.
2024-08-14 English
MYX announces patent lawsuit against Sun Pharmaceutical 2 pages 131.8KB
Legal Proceedings Report Classification · 95% confidence The document is an ASX announcement dated 25 July 2024 regarding Mayne Pharma filing a patent infringement lawsuit against Sun Pharmaceutical. It discusses the initiation of litigation under the Hatch-Waxman Act and provides background on the product IMVEXXY and the company. There are no financial statements, quarterly or annual results, or detailed financial data. The content focuses on legal proceedings related to intellectual property rights. The document length is 3229 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Legal Proceedings Report (LTR).
2024-07-24 English
Class action settlement 1 page 96.1KB
Legal Proceedings Report Classification · 95% confidence The document is an ASX announcement regarding a class action settlement involving Mayne Pharma Group Limited. It details the settlement amount, background of the legal proceeding, and the company's financial position related to the settlement. There is no presentation of financial statements, audit results, or detailed financial performance data. The document is primarily a legal proceedings update about a settlement agreement. It is not an annual report, earnings release, or any financial report. It fits best under Legal Proceedings Report (LTR) as it provides an update on a significant lawsuit and its resolution.
2024-07-01 English
MYX presentation at Jefferies Global Healthcare Conference 12 pages 1.1MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement titled 'Mayne Pharma Presentation at the 2024 Jefferies Global Healthcare Conference, New York City' dated 6 June 2024. It includes detailed presentation slides content such as company overview, market position, financial performance for 1HFY24, growth strategies, and product portfolio. The text explicitly states it is a presentation by the CEO at a healthcare conference and includes forward-looking statements and disclaimers typical of investor presentations. There are no indications that this is a full annual or interim report, audit report, or earnings release. The document is lengthy (15,000 characters) and contains substantive financial data and strategic information, consistent with an investor presentation. Therefore, the document fits the category of an Investor Presentation (IP).
2024-06-05 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.